SSC
BMRN icon

Syverson Strege & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Syverson Strege & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16
Closed -$1.56K – 135
2023
Q1 		$1.56K Buy
+16
New +$1.66K ﹤0.01% 537

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Syverson Strege & Co's BMRN Position: Q2 2023 in Review

Syverson Strege & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 16 shares — an estimated $1.56K sold.

Syverson Strege & Co first reported a position in BMRN in Q1 2023 and held it in 1 quarter. The position peaked at $1.56K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Syverson Strege & Co reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 16 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $1.56K.
  • Syverson Strege & Co first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's BioMarin Pharmaceuticals position peaked at $1.56K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.